These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 25761479)

  • 1. Antitumor Activity of HM781-36B, alone or in Combination with Chemotherapeutic Agents, in Colorectal Cancer Cells.
    Kang MH; Moon SU; Sung JH; Kim JW; Lee KW; Lee HS; Lee JS; Kim JH
    Cancer Res Treat; 2016 Jan; 48(1):355-64. PubMed ID: 25761479
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antitumor activity of HM781-36B, a pan-HER tyrosine kinase inhibitor, in HER2-amplified breast cancer cells.
    Kim HJ; Kim HP; Yoon YK; Kim MS; Lee GS; Han SW; Im SA; Kim TY; Oh DY; Bang YJ
    Anticancer Drugs; 2012 Mar; 23(3):288-97. PubMed ID: 23422737
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antitumor activity of HM781-36B, an irreversible Pan-HER inhibitor, alone or in combination with cytotoxic chemotherapeutic agents in gastric cancer.
    Nam HJ; Kim HP; Yoon YK; Hur HS; Song SH; Kim MS; Lee GS; Han SW; Im SA; Kim TY; Oh DY; Bang YJ
    Cancer Lett; 2011 Mar; 302(2):155-65. PubMed ID: 21306821
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antitumor activity of HM781-36B, a highly effective pan-HER inhibitor in erlotinib-resistant NSCLC and other EGFR-dependent cancer models.
    Cha MY; Lee KO; Kim M; Song JY; Lee KH; Park J; Chae YJ; Kim YH; Suh KH; Lee GS; Park SB; Kim MS
    Int J Cancer; 2012 May; 130(10):2445-54. PubMed ID: 21732342
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Epidermal growth factor receptor activity determines response of colorectal cancer cells to gefitinib alone and in combination with chemotherapy.
    Van Schaeybroeck S; Karaiskou-McCaul A; Kelly D; Longley D; Galligan L; Van Cutsem E; Johnston P
    Clin Cancer Res; 2005 Oct; 11(20):7480-9. PubMed ID: 16243822
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A small-molecule pan-HER inhibitor alone or in combination with cisplatin exerts efficacy against nasopharyngeal carcinoma.
    Yang J; Yang Y; Wei Y; Wei X
    Front Med; 2023 Apr; 17(2):275-289. PubMed ID: 36645632
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Metronomic 5-fluorouracil, oxaliplatin and irinotecan in colorectal cancer.
    Fioravanti A; Canu B; Alì G; Orlandi P; Allegrini G; Di Desidero T; Emmenegger U; Fontanini G; Danesi R; Del Tacca M; Falcone A; Bocci G
    Eur J Pharmacol; 2009 Oct; 619(1-3):8-14. PubMed ID: 19695243
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lapatinib, a dual inhibitor of EGFR and HER2, has synergistic effects with 5-fluorouracil on esophageal carcinoma.
    Guo XF; Zhu XF; Zhong GS; Deng BG; Gao ZT; Wang H
    Oncol Rep; 2012 May; 27(5):1639-45. PubMed ID: 22293713
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combined gefitinib and pemetrexed overcome the acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer.
    Wu M; Yuan Y; Pan YY; Zhang Y
    Mol Med Rep; 2014 Aug; 10(2):931-8. PubMed ID: 24840891
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Population pharmacokinetics of HM781-36 (poziotinib), pan-human EGF receptor (HER) inhibitor, and its two metabolites in patients with advanced solid malignancies.
    Noh YH; Lim HS; Jung JA; Song TH; Bae KS
    Cancer Chemother Pharmacol; 2015 Jan; 75(1):97-109. PubMed ID: 25377158
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synergistic interaction between the EGFR tyrosine kinase inhibitor gefitinib ("Iressa") and the DNA topoisomerase I inhibitor CPT-11 (irinotecan) in human colorectal cancer cells.
    Koizumi F; Kanzawa F; Ueda Y; Koh Y; Tsukiyama S; Taguchi F; Tamura T; Saijo N; Nishio K
    Int J Cancer; 2004 Jan; 108(3):464-72. PubMed ID: 14648715
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Activated Src and Ras induce gefitinib resistance by activation of signaling pathways downstream of epidermal growth factor receptor in human gallbladder adenocarcinoma cells.
    Qin B; Ariyama H; Baba E; Tanaka R; Kusaba H; Harada M; Nakano S
    Cancer Chemother Pharmacol; 2006 Nov; 58(5):577-84. PubMed ID: 16532343
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bcl-x(L) and Myeloid cell leukaemia-1 contribute to apoptosis resistance of colorectal cancer cells.
    Schulze-Bergkamen H; Ehrenberg R; Hickmann L; Vick B; Urbanik T; Schimanski CC; Berger MR; Schad A; Weber A; Heeger S; Galle PR; Moehler M
    World J Gastroenterol; 2008 Jun; 14(24):3829-40. PubMed ID: 18609706
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combined application of anti-VEGF and anti-EGFR attenuates the growth and angiogenesis of colorectal cancer mainly through suppressing AKT and ERK signaling in mice model.
    Ding C; Li L; Yang T; Fan X; Wu G
    BMC Cancer; 2016 Oct; 16(1):791. PubMed ID: 27729020
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Increased anticancer activity of the thymidylate synthase inhibitor BGC9331 combined with the topoisomerase I inhibitor SN-38 in human colorectal and breast cancer cells: induction of apoptosis and ROCK cleavage through caspase-3-dependent and -independent mechanisms.
    Coudray AM; Louvet C; Kornprobst M; Raymond E; André T; Tournigand C; Faivre S; De Gramont A; Larsen AK; Gespach C
    Int J Oncol; 2005 Aug; 27(2):553-61. PubMed ID: 16010439
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Metabolite identification of a new tyrosine kinase inhibitor, HM781-36B, and a pharmacokinetic study by liquid chromatography/tandem mass spectrometry.
    Kim E; Kim H; Suh K; Kwon S; Lee G; Park NH; Hong J
    Rapid Commun Mass Spectrom; 2013 Jun; 27(11):1183-95. PubMed ID: 23650031
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Curcumin enhances the effects of 5-fluorouracil and oxaliplatin in mediating growth inhibition of colon cancer cells by modulating EGFR and IGF-1R.
    Patel BB; Sengupta R; Qazi S; Vachhani H; Yu Y; Rishi AK; Majumdar AP
    Int J Cancer; 2008 Jan; 122(2):267-73. PubMed ID: 17918158
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lapatinib, a dual inhibitor of epidermal growth factor receptor and human epidermal growth factor receptor 2, potentiates the antitumor effects of cisplatin on esophageal carcinoma.
    Guo XF; Zhu XF; Zhong GS; Deng BG
    Dis Esophagus; 2013 Jul; 26(5):487-95. PubMed ID: 22458639
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Growth response of human colorectal tumour cell lines to treatment with afatinib (BIBW2992), an irreversible erbB family blocker, and its association with expression of HER family members.
    Khelwatty SA; Essapen S; Seddon AM; Modjtahedi H
    Int J Oncol; 2011 Aug; 39(2):483-91. PubMed ID: 21617858
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Responses of human colorectal tumor cells to treatment with the anti-epidermal growth factor receptor monoclonal antibody ICR62 used alone and in combination with the EGFR tyrosine kinase inhibitor gefitinib.
    Cunningham MP; Thomas H; Fan Z; Modjtahedi H
    Cancer Res; 2006 Aug; 66(15):7708-15. PubMed ID: 16885373
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.